Cytek Biosciences, Inc. (CTKB)
Cytek Biosciences, Inc. (CTKB) Q1 2026 Earnings Call Transcript
Cytek Biosciences, Inc. (CTKB) Q1 2026 Earnings Call Transcript
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates
Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.09 per share a year ago.
Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates
Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.02. This compares to earnings of $0.07 per share a year ago.
Cytek Biosciences, Inc. (CTKB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Cytek Biosciences, Inc. (CTKB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Cytek Biosciences Is A Speculative Buy On Recurring Revenue Growth
Cytek Biosciences offers a full-spectrum cytometry platform. This means they provide instruments, reagents, services, and cloud software. Their main value proposition is to allow clients to achieve higher-parameter cell analysis than conventional flow systems. Its core product portfolio centers around Aurora, Northern Lights, Aurora CS, and Aurora Evo. Each targets a different price-performance tier.
Cytek Biosciences, Inc. (CTKB) Q3 2025 Earnings Call Transcript
Cytek Biosciences, Inc. ( CTKB ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Paul Goodson Wenbin Jiang - President, CEO & Chairman of the Board William McCombe - Chief Financial Officer Conference Call Participants David Westenberg - Piper Sandler & Co., Research Division Brendan Smith - TD Cowen, Research Division Harrison Parsons - Stephens Inc., Research Division Noah Lewis - Raymond James & Associates, Inc., Research Division Presentation Operator Good day, everyone, and thank you for standing by. My name is Arjarie, and I will be your conference operator today.
Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates
Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.01. This compares to earnings of $0.01 per share a year ago.
Cytek Biosciences, Inc. (CTKB) Q2 2025 Earnings Call Transcript
Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Paul Goodson - Head of Investor Relations Wenbin Jiang - President, CEO & Chairman of the Board William D. McCombe - Chief Financial Officer Conference Call Participants Chad Wiatrowski - Unidentified Company David Michael Westenberg - Piper Sandler & Co., Research Division Operator Ladies and gentlemen, thank you for standing by.
Cytek Biosciences, Inc. (CTKB) Beats Q2 Earnings Estimates
Cytek Biosciences, Inc. (CTKB) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.08 per share a year ago.
Cytek Biosciences, Inc. (CTKB) Q1 2025 Earnings Call Transcript
Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Paul Goodson - IR Wenbin Jiang - CEO William McCombe - CFO Conference Call Participants David Westenberg - Piper Sandler Chad Wiatrowski - TD Cowen Andrew Cooper - Raymond James Operator Thank you for standing by. At this time, I would like to welcome everyone to the Cytek Biosciences First Quarter 2025 Earnings Conference Call.
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Lags Revenue Estimates
Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.05 per share a year ago.
Cytek Biosciences: With Growth, Low Debt, And A Positive Long-Term Outlook, Is It Undervalued?
The relative valuations conducted in this article suggest that Cytek presents an undervaluation in the range of 16.43% to 109.37%. Cytek has reported net losses due to its growth strategy. In fact, in 2024, its operating expenses represented 65.67% of its sales. In 2024, the company reported cash and cash equivalents and marketable securities of $277.86 million. Meanwhile, its total liabilities were $103.76 million in that year.
